Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005
Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Gabapentin for Parkinsonism:A Double-Blind Placebo-Controlled, Crossover Trial
Am J med 102:60-66, Olson,W.L.,et al, 1997
Serotonin Syndrome and the Combined Use of Deprenyl and An Antidepressant in Parkinson's Disease
Neurol 48:1070-1077, Richard,I.H.,et al, 1997
Reversible Parkinsonism and Cognitive Impairment with Chronic Valproate Use
Neurol 47:626-635, Armon,C.,et al, 1996
Intranasal Apomorphine in Parkinsonian On-Off Fluctuations
Arch Neurol 49:482-484, vanLaar,T.,et al, 1992
Acute Respiratory Failure from Dopamine Agonist Withdrawal
Neurol 42:1843-1844, Riley,D.E.,et al, 1992
Apomorphine Test for Dopaminergic Response in Pts with Previously Untreated Parkinson's
Arch Neurol 49:1131-1134, Gasser,T.,et al, 1992
Intranasal Apomorphine in Parkinson's Disease
Neurol 41:761-762, Kleedorfer,B.,et al, 1991
Movement Disorders in Alcoholism:A Review
Neurol 40:741-746, Neiman,J.,et al, 1990
Reappraisal of Temporary Levodopa Withdrawal ("Drug Holiday") in Parkinson's Disease
NEJM 313:724-728, Mayeux,R.,et al, 1985
"Drug Holiday"in the Treatment of Parkinson's Disease, A Brief Review
Arch Int Med 145:913-915, Friedman,J.H., 1985
Alternate Day Levodopa Therapy in Parkinsonism
Neurol 32:324-326, Koller,W.C., 1982
Complications of Chronic Levodopa Therapy; Long-term Efficacy of Drug Holiday
Neurol 31:473-476, Koller,W.C.,et al, 1981
Parkinsonism Provoked by Alcoholism
Ann Neurol 9:84-86, Carlen,P.L.,et al, 1981
Weekly Drug Holiday in Parkinson Disease
Neurol 31:1460-1462, Goetz,C.G.,et al, 1981
Is L-DOPA Drug Holiday Useful
Neurol 30:785-788, Direnfield,L.K.,et al, 1980
Drug Holiday & Management of Parkinson Disease
Neurol 30:1257-1261, Weiner,W.J.,et al, 1980
Drug Holidays for Patients with Parkinsonism
JAMA 242:17-21, Clark,W.A., 1979